Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Acquisitions & Divestments (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Change in Acquisitions & Divestments for 7 consecutive years, with -$378.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 306.6% to -$378.1 million in Q3 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a N/A change, with the full-year FY2025 number at $5.7 million, changed N/A from a year prior.
  • Change in Acquisitions & Divestments was -$378.1 million for Q3 2025 at Beam Therapeutics, down from $166.7 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $365.5 million in Q2 2023 to a low of -$935.0 million in Q4 2023.
  • A 5-year average of $91.6 million and a median of $183.0 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 683.91% in 2022, then plummeted 359.64% in 2023.
  • Beam Therapeutics' Change in Acquisitions & Divestments stood at $106.4 million in 2021, then skyrocketed by 238.59% to $360.1 million in 2022, then tumbled by 359.64% to -$935.0 million in 2023, then soared by 41.05% to -$551.1 million in 2024, then soared by 31.4% to -$378.1 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Change in Acquisitions & Divestments are -$378.1 million (Q3 2025), $166.7 million (Q2 2025), and $217.1 million (Q1 2025).